Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc.verified

CLDX

Price:

$25.39

Market Cap:

$1.68B

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, wh...[Read more]

Industry

Biotechnology

IPO Date

1986-05-15

Stock Exchange

NASDAQ

Ticker

CLDX

The Current Ratio as of November 2024 (TTM) for Celldex Therapeutics, Inc. (CLDX) is 29.36

According to Celldex Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 29.36. This represents a change of 40.07% compared to the average of 20.96 of the last 4 quarters.

Celldex Therapeutics, Inc. (CLDX) Historical Current Ratio (quarterly & annually)

How has CLDX Current Ratio performed in the past?

The mean historical Current Ratio of Celldex Therapeutics, Inc. over the last ten years is 11.22. The current 29.36 Current Ratio has changed 26.06% with respect to the historical average. Over the past ten years (40 quarters), CLDX's Current Ratio was at its highest in in the March 2024 quarter at 31.77. The Current Ratio was at its lowest in in the March 2020 quarter at 5.12.

Quarterly (TTM)
Annual

Average

11.22

Median

9.06

Minimum

5.22

Maximum

24.86

Celldex Therapeutics, Inc. (CLDX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Celldex Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 143.11%

Maximum Annual Current Ratio = 24.86

Minimum Annual Increase = -44.19%

Minimum Annual Current Ratio = 5.22

Quarterly (TTM)
Annual
YearCurrent RatioChange
202313.87-18.75%
202217.07-31.32%
202124.8678.49%
202013.93143.11%
20195.73-27.14%
20187.8650.64%
20175.22-6.00%
20165.55-43.07%
20159.7516.53%
20148.37-44.19%

Celldex Therapeutics, Inc. (CLDX) Average Current Ratio

How has CLDX Current Ratio performed in the past?

The current Current Ratio of Celldex Therapeutics, Inc. (CLDX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

18.60

5-year avg

15.09

10-year avg

11.22

Celldex Therapeutics, Inc. (CLDX) Current Ratio vs. Peers

How is CLDX’s Current Ratio compared to its peers?

Celldex Therapeutics, Inc.’s Current Ratio is greater than IDEAYA Biosciences, Inc. (22.93), greater than AnaptysBio, Inc. (9.09), greater than MeiraGTx Holdings plc (2.36), greater than Keros Therapeutics, Inc. (20.37), greater than Homology Medicines, Inc. (4.19), greater than Cerevel Therapeutics Holdings, Inc. (10.22), greater than Avidity Biosciences, Inc. (15.78), greater than Revolution Medicines, Inc. (15.42), greater than Day One Biopharmaceuticals, Inc. (14.62), greater than SpringWorks Therapeutics, Inc. (7.91), greater than Cytokinetics, Incorporated (10.39), greater than DICE Therapeutics, Inc. (25.88), less than Edgewise Therapeutics, Inc. (30.24), greater than Karuna Therapeutics, Inc. (19.31), greater than Dyne Therapeutics, Inc. (26.63), greater than Crinetics Pharmaceuticals, Inc. (16.09), greater than ALX Oncology Holdings Inc. (4.39), greater than Immatics N.V. (3.74), greater than BioAtla, Inc. (3.81), greater than Aerovate Therapeutics, Inc. (6.51), greater than Travere Therapeutics, Inc. (1.71), greater than Ventyx Biosciences, Inc. (14.19), greater than Cogent Biosciences, Inc. (9.25),

Build a custom stock screener for Celldex Therapeutics, Inc. (CLDX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Celldex Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Celldex Therapeutics, Inc. (CLDX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Celldex Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Current Ratio?

How can you use the Current Ratio?

What is Celldex Therapeutics, Inc.'s Current Ratio?

How is the Current Ratio calculated for Celldex Therapeutics, Inc. (CLDX)?

What is the highest Current Ratio for Celldex Therapeutics, Inc. (CLDX)?

What is the 3-year average Current Ratio for Celldex Therapeutics, Inc. (CLDX)?

What is the 5-year average Current Ratio for Celldex Therapeutics, Inc. (CLDX)?

How does the current Current Ratio for Celldex Therapeutics, Inc. (CLDX) compare to its historical average?